Urine from current smokers induces centrosome aberrations and spindle defects in vitro in nonmalignant human cell lines

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 253-262

  Gabriel, Ute ^a   Giehl, Michelle ^b   Haass, Wiltrud ^b   Trojan, Lutz ^a   Michel, Maurice Stephan ^a   Hofmann, Wolf Karsten ^b   Seifarth, Wolfgang ^b   Fabarius, Alice ^b  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CENTROSOME; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DNA DAMAGE; FIBROBLAST; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SMOKING; SPINDLE CELL;

ADULT; CARCINOGENS; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; CENTROSOME; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; MIDDLE AGED; MITOTIC SPINDLE APPARATUS; SKIN; SMOKING; UROTHELIUM;

NICOTIANA TABACUM;

EID: 78650025445     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.07.135     Document Type: Article

References (53)

1. Ferlay J., Randi G., Bosetti C., Levi F., Negri E., Boyle P., et al. Declining mortality from bladder cancer in Europe. BJU Int 2008, 101:11-19.
2. Case R.A., Hosker M.E., McDonald D.B., Pearson J.T. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med 1954, 11:75-104.
3. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004, 83. 1-1438.
4. Clavel J., Cordier S., Boccon-Gibod L., Hemon D. Tobacco and bladder cancer in males: increased risk for inhalers and smokers of black tobacco. Int J Cancer 1989, 44:605-610.
5. Baris D., Karagas M.R., Verrill C., Johnson A., Andrew A.S., Marsit C.J., et al. A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst 2009, 101:1553-1561.
6. Gandini S., Botteri E., Iodice S., Boniol M., Lowenfels A.B., Maisonneuve P., et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008, 122:155-164.
7. Shen Y.M., Troxel A.B., Vedantam S., Penning T.M., Field J. Comparison of p53 mutations induced by PAH o-quinones with those caused by anti-benzo[a]pyrene diol epoxide in vitro: role of reactive oxygen and biological selection. Chem Res Toxicol 2006, 19:1441-1450.
8. Pavanello S., Pulliero A., Saia B.O., Clonfero E. Determinants of anti-benzo[a]pyrene diol epoxide-DNA adduct formation in lymphomonocytes of the general population. Mutat Res 2006, 611:54-63.
9. Florl A.R., Schulz W.A. Chromosomal instability in bladder cancer. Arch Toxicol 2008, 82:173-182.
10. Mitelman Database of chromosome aberrations and gene fusions in cancer 2004, Available at. http://cgap.nci.nih.gov/chromosomes/mitelman, F. Mitelman, B. Johansson, F. Mertens (Eds.).
11. Fadl-Elmula I., Kytölä S., Pan Y., Lui W.O., Derienzo G., Forsberg L., et al. Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysis. Int J Cancer 2001, 92:824-831.
12. Santos L., Pereira S., Leite R.P., Souto M., Amaro T., Criado B. Chromosome instability and progression in urothelial cell carcinoma of the bladder. Acta Oncol 2003, 42:169-173.
13. Giehl M., Fabarius A., Frank O., Hochhaus A., Hafner M., Hehlmann R., et al. Centrosome aberrations in chronic myeloid leukemia correlate with disease progression and chromosomal instability. Leukemia 2005, 19:1192-1197.
14. Pihan G.A., Purohit A., Wallace J., Malhotra R., Liotta L., Doxsey S.J. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 2001, 61:2212-2219.
15. Schneeweiss A., Sinn H.P., Ehemann V., Khbeis T., Neben K., Krause U., et al. Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer 2003, 107:346-352.
16. Sato N., Mizumoto K., Nakamura M., Nakamura K., Kusumoto M., Niiyama H., et al. Centrosome abnormalities in pancreatic ductal carcinoma. Clin Cancer Res 1999, 5:963-970.
17. Krämer A., Schweizer S., Neben K., Giesecke C., Kalla J., Katzenberger T., et al. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma. Leukemia 2003, 17:2207-2213.
18. Neben K., Giesecke C., Schweizer S., Ho A.D., Krämer A. Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile. Blood 2003, 101:289-291.
19. Brinkley B.R. Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol 2001, 11:18-21.
20. Yamamoto Y., Eguchi S., Junpei A., Nagao K., Sakano S., Furuya T., et al. Intercellular centrosome number is correlated with the copy number of chromosomes in bladder cancer. Cancer Genet Cytogenet 2009, 191:38-42.
21. Fabarius A., Giehl M., Frank O., Duesberg P., Hochhaus A., Hehlmann R., et al. Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 2005, 19:1573-1578.
22. Fabarius A., Giehl M., Frank O., Spiess B., Zheng C., Müller M.C., et al. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with spindle defects and genetic instability. Br J Haematol 2007, 138:369-373.
23. Fabarius A., Giehl M., Rebacz B., Krämer A., Frank O., Haferlach C., et al. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 2008, 93:1145-1154.
24. Giehl M., Fabarius A., Frank O., Erben P., Zheng C., Hafner M., et al. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. Leukemia 2007, 21:1971-1976.
25. Petzoldt J.L., Leigh I.M., Duffy P.G., Sexton C., Masters J.R. Immortalisation of human urothelial cells. Urol Res 1995, 23:377-380.
26. Frank M.B., Yang Q., Osban J., Azzarello J.T., Saban M.R., Saban R., et al. Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity. BMC Complement Altern Med 2009, 9:6.
27. Rossi M.R., Masters J.R., Park S., Todd J.H., Garrett S.H., Sens M.A., et al. The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect 2001, 109:801-808.
28. Eblin K.E., Bredfeldt T.G., Gandolfi A.J. Immortalized human urothelial cells as a model of arsenic-induced bladder cancer. Toxicology 2008, 248:67-76.
29. ISCN: an international system for human cytogenetic nomenclature 2009, S. Karger, Basel. L.G. Schaffer, M.L. Slovak, L.J. Campbell (Eds.).
30. Brennan P., Bogillot O., Cordier S., Greiser E., Schill W., Vineis P., et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000, 86:289-294.
31. Brennan P., Bogillot O., Greiser E., Chang-Claude J., Wahrendorf J., Cordier S., et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 2001, 12:411-417.
32. Smith C.J., Perfetti T.A., Garg R., Hansch C. IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. Food Chem Toxicol 2003, 41:807-817.
33. Mattammal M.B., Lakshmi V.M., Zenser T.V., Davis B.B. Metabolism of aromatic and heterocyclic amine bladder carcinogens: bioanalytical considerations. J Pharm Biomed Anal 1990, 8:151-158.
34. Massadeh A.M., Gharaibeh A.A., Omari K.W. A single-step extraction method for the determination of nicotine and cotinine in Jordanian smokers' blood and urine samples by RP-HPLC and GC-MS. J Chromatogr Sci 2009, 47:170-177.
35. Riedel K., Scherer G., Engl J., Hagedorn H.W., Tricker A.R. Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol 2006, 3:187-195.
36. Crallan R.A., Georgopoulos N.T., Southgate J. Experimental models of human bladder carcinogenesis. Carcinogenesis 2006, 27:374-381.
37. Degen G.H., Schlattjan J.H., Mahler S., Follmann W., Golka K. Comparative metabolic activation of benzidine and N-acetylbenzidine by prostaglandin H synthase. Toxicol Lett 2004, 151:135-142.
38. Hecht S.S. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002, 23:907-922.
39. Jiang F., Caraway N.P., Sabichi A.L., Zhang H.Z., Ruitrok A., Grossman H.B., et al. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer 2003, 106:661-665.
40. Li J.J., Li S.A. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 2006, 111:974-984.
41. Dodson H., Bourke E., Jeffers L.J., Vagnarelli P., Sonoda E., Takeda S., et al. Centrosome amplification induced by DNA damage occurs during a prolonged G2 phase and involves ATM. EMBO J 2004, 23:3864-3873.
42. Borel F., Lohez O.D., Lacroix F.B., Margolis R.L. Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc Natl Acad Sci U S A 2002, 99:9819-9824.
43. Kawamura K., Fujikawa-Yamamoto K., Ozaki M., Iwabuchi K., Nakashima H., Domiki C., et al. Centrosome hyperamplification and chromosomal damage after exposure to radiation. Oncology 2004, 67:460-470.
44. Schulz W.A. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006, 119:1513-1518.
45. Knowles M.A. Tumor suppressor loci in bladder cancer. Front Biosci 2007, 12:2233-2251.
46. Tsou M.F., Wang W.J., George K.A., Uryu K., Stearns T., Jallepalli P.V. Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells. Dev Cell 2009, 17:344-354.
47. Lampson M.A., Kapoor T.M. The human mitotic checkpoint protein BubR1 regulates chromosome-spindle attachments. Nat Cell Biol 2005, 7:93-98.
48. Yamamoto Y., Matsuyama H., Chochi Y., Okuda M., Kawauchi S., Inoue R., et al. Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet 2007, 174:42-47.
49. Yamamoto Y., Matsuyama H., Kawauchi S., Matsumoto H., Nagao K., Ohmi C., et al. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006, 70:231-237.
50. Grignon DJ. The current classification of urothelial neoplasms. Mod Pathol 2009;22 Suppl 2:60-9.
51. Penning T.M., Lerman C. Genomics of smoking exposure and cessation: lessons for cancer prevention and treatment. Cancer Prev Res (Phila Pa) 2008, 1:80-83.
52. Florescu A., Ferrence R., Einarson T., Selby P., Soldin O., Koren G. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther Drug Monit 2009, 31:14-30.
53. Bardelli A., Cahill D.P., Lederer G., Speicher M.R., Kinzler K.W., Vogelstein B., et al. Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A 2001, 98:5770-5775.